EGFR L858R

Nearly 7% of EGFR mutations in NSCLC patients were compound mutations, which is comparable to previous reports. The presence of multiple mutations, particularly those involving T790M , may be associated with potential resistance to first-line EGFR -TKIs. We describe a triple mutation involving del19 + G719X + S768I , which represents an uncommon scenario.

P3, N=878, Recruiting, AstraZeneca | Trial completion date: Mar 2030 --> Nov 2030 | Trial primary completion date: May 2029 --> Nov 2030

This case demonstrates the efficacy of genotype-guided targeted therapy in the management of recurrent lung adenocarcinoma presenting with brain metastases and pericardial effusion. The rapid and complete resolution of brain metastases and marked improvement in pericardial effusion within two weeks of initiating almonertinib therapy underscore the pivotal role of molecular profiling in guiding personalized treatment for advanced EGFR-mutated NSCLC. It also emphasizes the importance of rigorous postoperative surveillance for early detection of recurrence, thereby facilitating timely intervention and optimizing clinical outcomes in patients with advanced NSCLC.

This study supports the real-world effectiveness and tolerability of first-line osimertinib. Oligoprogression was associated with longer OS compared with systemic progression, and the integration of LATs in carefully selected patients with oligoprogression may be associated with prolonged osimertinib treatment duration and favorable post-progression outcomes.

Examination of their electronic structure via density functional theory revealed efficient properties, with the highest occupied molecular orbital-least unoccupied molecular orbital energy gap values ranging from -3.984 eV to -6.547 eV. Further, in vivo analysis is required to gain a more comprehensive understanding and efficacy of these identified phytochemicals against lung cancer.

P2, N=36, Active, not recruiting, Shandong Cancer Hospital and Institute

P2/3, N=410, Recruiting, Sinocelltech Ltd.

P1, N=42, Recruiting, Alpha Biopharma (Jiangsu) Co., Ltd. | Not yet recruiting --> Recruiting

P1/2, N=32, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028

P2, N=50, Recruiting, Taipei Medical University Hospital | Not yet recruiting --> Recruiting

Our findings demonstrate that compound EGFR mutations comprise distinct subgroups with unique clinical characteristics and different responses to targeted therapy. For example, osimertinib may be a viable treatment for patients with compound G719X/L861Q mutations. Further characterization of these heterogeneous subgroups is warranted for identifying optimal treatment strategies as novel targeted agents emerge.

In a small-sample-size test, the ESEA system achieved 100% sensitivity and specificity in pleural effusion samples (n=5) and a 100% ctDNA detection rate in patients with extracranial lesions and disease progression (n=6). These results highlight its potential as a cost-effective, highly sensitive, and robust platform for dynamic, real-time companion diagnostics, as well as non-invasive monitoring of treatment response and tumor evolution.